Supplementary Figure Legend from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
Tomoko Smyth, Nicola G. Wallis(Biota Pharmaceuticals (United States)), Thomas Van Looy(KU Leuven), Patrick Schöffski(KU Leuven), Rachel Donsky(Brigham and Women's Hospital), Jennifer G. Morgan(Brigham and Women's Hospital), John S. Lyons(University of Chicago), Jayne Curry(Brigham and Women's Hospital), Mei‐Jun Zhu(Washington State University), Agnieszka Woźniak(VIB-KU Leuven Center for Cancer Biology), Ana M. Rodrı́guez-López(Brigham and Women's Hospital), Mark Mayeda(Brigham and Women's Hospital), Jonathan A. Fletcher(Harvard University), Neil T. Thompson(University of Cambridge)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716